pralsetinib: Clinical Trials

7 trials of pralsetinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 2 recruiting, 1 unknown. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Active not recruiting 2, Completed 2, Recruiting 2, Unknown 1
Phase 11Completed 1

Follow pralsetinib: new trials by email Literature Review of pralsetinib trials Research Report on pralsetinib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
Sunvozertinib, Crizotinib, Pralsetinib - Lung Cancer Stage III, Mutation
Phase 2RecruitingSun Yat-sen University1202024-11-012026-04-21
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma
Phase 2RecruitingWest China Hospital752021-06-012024-12-05
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Entrectinib, Alectinib, Atezolizumab - Solid Tumors
Phase 2Active not recruitingHoffmann-La Roche9202021-01-182026-09-04
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy
Phase 2CompletedGenentech, Inc.2522021-01-132025-01-08
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer
Phase 2Active not recruitingGenentech, Inc.992020-11-062026-11-10
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2CompletedHoffmann-La Roche5902017-03-172025-05-31

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Gastrointestinal Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma, Papillary (1)  ·  Breast Neoplasms (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Medullary (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Colonic Diseases (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Digestive System Diseases (1)

Sponsors

Genentech, Inc. (2)  ·  Hoffmann-La Roche (2)  ·  Fondazione per la Medicina Personalizzata (1)  ·  Sun Yat-sen University (1)  ·  West China Hospital (1)

Countries

China (4)  ·  United States (4)  ·  Italy (3)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Hong Kong (2)  ·  Singapore (2)  ·  South Korea (2)  ·  Spain (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)

Top investigators

Andrea Botticelli (1)  ·  Paolo Marchetti (1)  ·  Si-Yu Wang, MD (1)  ·  Zhihui Li, Professor (1)

Results publications

PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40086048, PMID 40304938, PMID 40639400, PMID 41023484, PMID 41213248, PMID 41392942, PMID 41886723, PMID 41963505

NIH funding

2016 (1), 2018 (1), 2023 (1)